December 12, 202311:00 AM - 3:30 PM ET
This comprehensive half-day virtual course will explore the emerging challenges in HIV medicine, including a discussion of the implication of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) study, extending the discussion beyond the primary data; crucial aspects of managing substance use disorder (SUD) in individuals with HIV; sexually transmitted infections (STIs) management; future of antiretroviral therapy; and the use of GLP-1 agonists for people with HIV, including diabetes, weight loss, potential treatment for addictions, and other applications being considered for research.
Assessment of Needs
Rapid advances in HIV disease management require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV and address other emerging challenges in HIV medicine. Information will be presented through a mix of didactic lectures, clinically relevant cases, and expert discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.
After participating in the activity, learners will be able to:
- Integrate the study findings from the REPRIEVE trial into the treatment plans for adult patients with HIV
- Initiate treatment for substance use disorder (SUD) in patients with HIV and consider alternative plans to help patients stay retained in care
- Describe how and when to utilize doxycycline post-exposure prophylaxis (doxy-PEP) to reduce the incidence of STIs
- Evaluate results of recent clinical trials of new or novel antiretroviral drugs in development for treatment of HIV and their potential role(s) in future clinical practice
- Describe the current research of GLP-1 agonists therapy for people with HIV
- Overview of the REPRIEVE study and beyond
- Substance use disorder (SUD) management in people with HIV
- What’s new and hot in routine STIs management
- Future of Antiretroviral Therapy
- GLP-1 agonists for people with HIV, including diabetes, weight loss, potential treatment for addictions, and other applications being considered for research
Conflicts of Interest
In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.
The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content.
Who Should Attend
This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:
- Have a solid, working knowledge of HIV disease management
- Provide comprehensive or specialty care for patients with HIV infection
- Are currently active in HIV research
This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.
Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.
Cancellation requests must be made 7 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.
These activities are eligible for ANCC credit, see final CNE activity announcement for specific details.
These activities are eligible for ACPE credit, see final CPE activity announcement for specific details.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc.
Merck & Co, Inc.
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at firstname.lastname@example.org or 415-544-9400.